By: Charley Grant
The FDA seems likely to approve an experimental gene therapy to treat a rare disease. That is translating to big gains for Sarepta Therapeutics shareholders. The biotech company’s shares were up nearly 30% in early trading Monday, after a panel of outside experts voted 8-to-6 to recommend approval